GlassScriptPhysician profile
Robin F Spiering
NPI 1467458729
$11,078.14
in general payments reported to CMS, 2019-2025
50 companies · $1,255 in 2025
The $1,255 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,660 · 2020: $1,287 · 2021: $1,971 · 2022: $1,530 · 2023: $1,982 · 2024: $1,392 · 2025: $1,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,629.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,512.48 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,405.61 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,042.64 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $841.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $789.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $718.66 | 2019-2025 | Jardiance, Spiriva Respimat, Synjardy |
| Amgen INC. | $701.10 | 2019-2024 | Repatha, Otezla, Evenity |
| Pfizer INC. | $570.67 | 2019-2025 | |
| Esperion Therapeutics, INC. | $502.58 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $365.50 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi-Aventis U.S. LLC | $304.95 | 2019-2022 | |
| Boston Scientific Corporation | $299.31 | 2019-2025 | Watchman Flx, Farapulse |
| Amarin Pharma, INC. | $292.43 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $160.41 | 2019-2022 | |
| Allergan, INC. | $151.20 | 2019-2020 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Spiering listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.